Medytox Affiliate Newmeco Obtains Domestic Approval for Next-Generation Toxin 'Newlux'

Mass Production Begins at Medytox Plant 3
"Securing Core Growth Engine... Aiming to Reclaim No.1 in Korea"

Medytox announced that its affiliate Newmeco obtained product approval for the botulinum toxin (BTX) formulation 'Newlux' from the Ministry of Food and Drug Safety on the 31st.

NewMeco, a subsidiary of Medytox, presents the next-generation botulinum toxin product 'NEWLUX'.
[Photo by NewMeco]

Newmeco's first BTX formulation, Newlux, is a next-generation toxin in a freeze-dried form, which the company explained embodies the research and development (R&D) capabilities and know-how of both Medytox and Newmeco. Newlux enhances safety by excluding animal-derived ingredients during the raw material production process. Additionally, it minimizes the denaturation of the active neurotoxin protein through a non-chemical processing method while applying the latest manufacturing processes to improve production yield and quality (purity).

Newmeco plans to produce Newlux at Medytox's third plant, which has production facilities worth 600 billion KRW annually. The goal is to rapidly expand market share through mass production from the initial launch.

The company is also pursuing overseas expansion. It has already completed strategies for obtaining approvals by country, selecting regions such as Thailand and Brazil, where quick entry is possible in connection with domestic approval. Plans are also in place to enter advanced markets such as the United States and Europe. As Medytox is preparing to apply for approval of the liquid toxin formulation 'MT10109L' in the U.S., Newmeco intends to separately promote the entry of the freeze-dried formulation Newlux into advanced markets.

Joo Hee-seok, CEO of Newmeco, said, "With the domestic approval of the next-generation toxin formulation Newlux, we have secured a core driving force for future growth," adding, "This will be a major stepping stone for Medytox and Newmeco to establish themselves as absolute leaders in the domestic and overseas toxin markets."

CEO Joo continued, "We will actively utilize Newmeco's strong sales and marketing capabilities to grow Newlux into the number one toxin formulation domestically within a short period," emphasizing, "We will focus on completing a mass production system and shortening the launch schedule to reshape the domestic toxin market."

Meanwhile, Newlux is a next-generation BTX formulation developed by Newmeco aiming for domestic approval after technology transfer of the next-generation toxin candidate 'MBA-P01' from Medytox. With the product approval of Newlux, Medytox and Newmeco have succeeded in developing four BTX formulations.

This content was produced with the assistance of AI translation services.